News Presentations Publications

FILTERS

TOPICS

CritiTech PES partner NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

Intratumoral injection of three concentrations of NanoPac successfully completed across a total of 9 patients Highest concentration of NanoPac continues … Continued

More >

NanoPac® Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model

Background: NanoPac® is patented submicron particle paclitaxel in stable powder form without coating or carrier agents. In a previous PK study, … Continued

More >

Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm

NanOlogy™, a clinical-stage pharmaceutical development company, was formed in 2015 to increase the effectiveness and safety of CT through targeted … Continued

More >

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac) in a Rodent Model

Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The … Continued

More >

Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

Suspensions of submicron particle taxanes (Figure 1) allow for direct administration of high, sustained levels of chemotherapeutics at the site … Continued

More >

CritiTech PES partner NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer

NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor … Continued

More >

CritiTech PES partner NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* … Continued

More >

Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy

The combination of chemotherapies and immunotherapies highlights the significance of small molecule drug development as an ongoing treatment modality. Although … Continued

More >

CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019

FOR IMMEDIATE RELEASEOctober 24, 2018 CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019 CritiTech Particle Engineering Solutions was … Continued

More >

CritiTech Particle Engineering Solutions Launches New Pharmaceutical Spray Drying Business

FOR IMMEDIATE RELEASEMay 30, 2018 LAWRENCE, KS – CritiTech Particle Engineering Solutions, a growing Contract Development Manufacturing Organization (CDMO) and … Continued

More >